视神经脊髓炎谱系病的发病机制及免疫序贯治疗的研究进展  

Recent adanvces in pathogenesis and immunological sequential therapy of neuromyelitis optica spectrum disorder

作　　者：吴雨晴 林柳余 杭海伦 陆杰[1] Wu Yuqing;Lin Liuyu;Hang Hailun;Lu Jie(Department of Neurology,Brain Hospital Affiliated to Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学附属脑科医院神经内科,南京210029

出　　处：《中华神经医学杂志》2022年第10期1067-1072,共6页Chinese Journal of Neuromedicine

基　　金：江苏省青年医学人才(QNRC2016052)。

摘　　要：视神经脊髓炎谱系病(NMOSD)是一种自身免疫介导的中枢神经系统炎性脱髓鞘疾病, 其发病机制错综复杂, 主要与水通道蛋白4抗体相关。NMOSD病程常呈复发性, 可导致神经功能缺损进行性加重, 因此预防复发是NMOSD治疗的关键。除传统非特异性免疫抑制剂外, 新型靶向药物因疗效显著、不良反应较少也逐渐在NMOSD的序贯治疗方面展示出独特的优越性。本文以NMOSD的发病机制及其免疫序贯治疗药物的安全性和有效性为主要内容对相关研究综述如下。Neuromyelitis optica spectrum disorder(NMOSD)is an autoimmune inflammatory demyelinating disease of the central nervous system.Its pathogenesis is complex and mainly related to aquaporin 4 antibody.NMOSD typically follows a relapsing course leading to progressive aggravation of neurological deficits,making prevention of relapse being the key to NMOSD treatment.In addition to traditional non-specific immunosuppressants,new targeted drugs have gradually shown unique advantages in sequential treatment of NMOSD due to their significant efficacy and fewer adverse reactions.This article summarizes and reviews the pathogenesis of NMOSD and the safety and efficacy of immunosequential therapy drugs.

关 键 词：视神经脊髓炎谱系病 水通道蛋白4抗体 发病机制 序贯治疗 

分 类 号：R744.52[医药卫生—神经病学与精神病学]